Open AccessP1061: INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB‐EXPOSED MYELOFIBROSIS PATIENTS
Author(s) -
Abraham P.,
Liao X.,
Chevli M.,
Smith S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847112.18637.3d
Subject(s) - ruxolitinib , medicine , myelofibrosis , myeloproliferative neoplasm , population , international prognostic scoring system , oncology , bone marrow , myelodysplastic syndromes , environmental health